体外研究 8 种抗真菌药物对 55 株绵状嗜皮菌属临床分离株的活性
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
机构信息
CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1636-8. doi: 10.1128/AAC.01655-09. Epub 2010 Jan 19.
Abstract
The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n = 21), Fonsecaea monophora (n = 25), and Fonsecaea nubica (n = 9) were tested. The resulting MIC(90)s for all strains (n = 55) were as follows, in increasing order: posaconazole, 0.063 microg/ml; itraconazole, 0.125 microg/ml; isavuconazole, 0.25 microg/ml; voriconazole, 0.5 microg/ml; amphotericin B, 2 microg/ml; caspofungin, 2 microg/ml; anidulafungin, 2 microg/ml; and fluconazole, 32 microg/ml.
摘要
检测了 8 种抗真菌药物对 21 株佩氏利什曼原虫、25 株单孢子利什曼原虫和 9 株古巴利什曼原虫临床分离株的体外活性。所有菌株（n=55）的 MIC90 值如下，按升序排列：泊沙康唑，0.063μg/ml；伊曲康唑，0.125μg/ml；伊沙康唑，0.25μg/ml；伏立康唑，0.5μg/ml；两性霉素 B，2μg/ml；卡泊芬净，2μg/ml；阿尼芬净，2μg/ml；氟康唑，32μg/ml。
相似文献
1
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
Antimicrob Agents Chemother. 2010 Apr;54(4):1636-8. doi: 10.1128/AAC.01655-09. Epub 2010 Jan 19.
2
In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.
Antimicrob Agents Chemother. 2013 Apr;57(4):1974-7. doi: 10.1128/AAC.02114-12. Epub 2013 Feb 4.
3
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
Antimicrob Agents Chemother. 2015 Dec;59(12):7818-22. doi: 10.1128/AAC.01733-15. Epub 2015 Sep 14.
4
Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.
PLoS Negl Trop Dis. 2018 Jul 26;12(7):e0006675. doi: 10.1371/journal.pntd.0006675. eCollection 2018 Jul.
5
In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
Antimicrob Agents Chemother. 2013 Dec;57(12):6395-8. doi: 10.1128/AAC.01629-13. Epub 2013 Oct 7.
6
In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.
Antimicrob Agents Chemother. 2012 Nov;56(11):6044-7. doi: 10.1128/AAC.01112-12. Epub 2012 Sep 4.
7
In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates.
Antimicrob Agents Chemother. 2015 Oct;59(10):6642-5. doi: 10.1128/AAC.01218-15. Epub 2015 Aug 3.
8
In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Chin Med J (Engl). 2010 Oct;123(19):2706-9.
9
In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Antimicrob Agents Chemother. 2015 Sep;59(9):5827-9. doi: 10.1128/AAC.00978-15. Epub 2015 Jun 22.
10
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006.
引用本文的文献
1
Establishment of epidemiological cutoff values for , the primary etiologic agent of chromoblastomycosis, and eight antifungal medications.
J Clin Microbiol. 2025 May 14;63(5):e0190324. doi: 10.1128/jcm.01903-24. Epub 2025 Apr 4.
2
Antifungal Susceptibility of Melanized Fungi Isolated from CARD9 Deficient Patients: Implications for Treatment of Refractory Infections.
Mycopathologia. 2025 Feb 28;190(2):29. doi: 10.1007/s11046-025-00936-8.
3
Molecular Identification of Fonsecaea monophora, Novel Agent of Fungal Brain Abscess.
Emerg Infect Dis. 2024 Jun;30(6):1232-1235. doi: 10.3201/eid3006.240077.
4
Resazurin to determine the minimum inhibitory concentration on antifungal susceptibility assays for Fonsecaea sp. using a modified EUCAST protocol.
Braz J Microbiol. 2024 Jun;55(2):1349-1357. doi: 10.1007/s42770-024-01293-2. Epub 2024 Mar 4.
5
Antifungal Susceptibility and Biological Characteristics of Causing Cerebral Phaeohyphomycosis in Jinhua, China.
Infect Drug Resist. 2023 Nov 9;16:7187-7195. doi: 10.2147/IDR.S425961. eCollection 2023.
6
Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.
J Fungi (Basel). 2023 Jul 16;9(7):753. doi: 10.3390/jof9070753.
7
Molecular epidemiology and clinical-laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil.
Mycoses. 2022 Dec;65(12):1146-1158. doi: 10.1111/myc.13505. Epub 2022 Sep 29.
8
Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases.
Front Cell Infect Microbiol. 2022 Feb 18;12:810604. doi: 10.3389/fcimb.2022.810604. eCollection 2022.
9
Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.
J Immunol Res. 2021 Nov 1;2021:9742832. doi: 10.1155/2021/9742832. eCollection 2021.
10
Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0054621. doi: 10.1128/AAC.00546-21.
本文引用的文献
1
Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis.
Curr Opin Infect Dis. 2009 Dec;22(6):559-63. doi: 10.1097/QCO.0b013e328332bbc5.
2
Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophora.
Med Mycol. 2010 Mar;48(2):390-3. doi: 10.1080/13693780903008813.
3
In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.
Med Mycol. 2009 Feb;47(1):35-40. doi: 10.1080/13693780802566333.
4
Genetic diversity and species delimitation in the opportunistic genus Fonsecaea.
Med Mycol. 2009 Feb;47(1):17-25. doi: 10.1080/13693780802527178. Epub 2008 Dec 19.
5
Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment.
Med Mycol. 2009 Feb;47(1):3-15. doi: 10.1080/13693780802538001. Epub 2008 Dec 9.
6
Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Future Microbiol. 2008 Dec;3(6):603-15. doi: 10.2217/17460913.3.6.603.
7
In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China.
Med Mycol. 2008 Nov;46(7):745-7. doi: 10.1080/13693780802163438.
8
Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.
Rev Inst Med Trop Sao Paulo. 2005 Nov-Dec;47(6):339-46. doi: 10.1590/s0036-46652005000600006.
9
Management of chromoblastomycosis: novel perspectives.
Curr Opin Infect Dis. 2006 Apr;19(2):148-52. doi: 10.1097/01.qco.0000216625.28692.67.
10
Posaconazole: a broad-spectrum triazole antifungal.
Lancet Infect Dis. 2005 Dec;5(12):775-85. doi: 10.1016/S1473-3099(05)70297-8.
Zotero 插件